Harvard Bioscience outlines 2026 guidance with 2%-4% revenue growth and high-margin focus following structural improvements
Source: SeekingAlpha
2026-03-12 10:03:13 ET
More on Harvard Bioscience
- Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
- Harvard Bioscience announces 1-for-10 reverse stock split
- Seeking Alpha’s Quant Rating on Harvard Bioscience
- Historical earnings data for Harvard Bioscience
- Financial information for Harvard Bioscience
Read the full article on Seeking Alpha
For further details see:
Harvard Bioscience outlines 2026 guidance with 2%–4% revenue growth and high-margin focus following structural improvements
Harvard Bioscience Inc.
NASDAQ: HBIO
HBIO Trading
-3.3% G/L:
$6.155 Last:
7,154 Volume:
$6.43 Open:
HBIO Latest News
April 28, 2026 07:30:00 am
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
HBIO Stock Data
$28,178,005
35,641,756
0.25%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Holliston
